Genpact stock has delivered a decline of about 25% over the past 5 years, yet the broader valuation checks still lean cheap, which puts the recent share price recovery in sharp focus for investors trying to judge value today.

• Over 5 years, Genpact’s share price is down about 24.9%, which raises the question of whether sentiment has been too harsh on the stock.
• Expectations for growth in higher value technology focused services can support the case for further upside, while any slowdown in that shift away from legacy work may cap how much investors are willing to pay.
• Genpact screens as undervalued on most of Simply Wall St’s checks, with the company passing 5 of 6 broad valuation tests according to the value score, which suggests the stock still leans cheap rather than expensive.

The issue now is whether Genpact’s recent rebound is the start of a repricing toward its fundamentals or already reflects most of the value that the current checks suggest.

Is Genpact Still Cheap on Earnings?

The P/E ratio is a useful anchor for Genpact because earnings remain a key way many investors value established service companies. Genpact currently trades at a P/E of about 10.8x. That sits well below the Professional Services industry average of roughly 23.2x and also under the peer group average of about 16.9x. On simple comparison, the stock is priced at a discount to what investors are paying for many similar companies.

The fair P/E for Genpact, based on its growth profile, margins, scale and risk factors, is estimated at about 19.6x. This is still much higher than the current 10.8x multiple. Even after the recent share price recovery and the stronger second quarter 2026 results, the market P/E continues to sit well under this fair level, which points to a valuation that does not fully reflect those fundamentals.

On the P/E multiple, Genpact stock appears undervalued compared with both tailored fair value estimates and wider industry benchmarks.

The Genpact Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation checks for Genpact leave off and outline which paths for growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today, based on assumptions investors can inspect on the Community page. Each narrative links its number to a clear view on how Genpact's growth, profitability and risk profile might shift, which you can revisit as new information becomes available.

The community is split on Genpact, with one camp seeing AI led transformation and buybacks as support for more upside while the other worries that execution and economics could limit the payoff.

Bull case: 8% undervalued

"Ongoing investments in AI focused talent and the scaling of the "AI Gigafactory" (now with 100+ new AI leaders and over 270 Gen AI solutions deployed) are enhancing Genpact's ability to capture premium contracts across multiple sectors, bolstering future deal conversion and supporting sustained growth and EPS acceleration…"

Bear case: 17% overvalued

"Although non FTE, outcome based and consumption models already represent a significant share of revenue and generally support margin improvement, these models also shift more delivery and performance risk to Genpact…"

Do you think there's more to the story for Genpact? Head over to our Community to see what others are saying!

The Bottom Line

Genpact still screens as undervalued on market multiples, even after the recent share price recovery. The key question is whether the shift toward higher value, technology focused work and AI related services can keep earnings quality and growth prospects strong enough for the P/E to move closer to peers. If that transition progresses well, the current discount may look like an opportunity rather than a warning. If execution on AI, new delivery models and contract risk management disappoints, the lower multiple could prove to be the right price for the business.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.